CTOs on the Move

AllStripes

www.allstripes.com

 
AllStripes is a healthcare technology company dedicated to unlocking new treatments for people with rare diseases. AllStripes has developed a technology platform that generates regulatory-ready evidence to accelerate rare disease research and drug development, as well as a patient application that empowers patients and families to securely participate in treatment research online and benefit from their own medical data. AllStripes was founded by CEO Nancy Yu and technology developer Onno Faber, following his diagnosis and journey with the rare disease neurofibromatosis type 2. The company is backed by Lux Capital, JAZZ Venture Partners, Spark Capital, Medidata Solutions, McKesson Ventures, Maveron, ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.allstripes.com
  • 121 2nd Street Suite 700
    San Francisco, CA USA 94105
  • Phone: 415.404.9287

Executives

Name Title Contact Details

Similar Companies

Synaptogenix

Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders.

SkinMedica

SkinMedica, Inc. is a specialty pharmaceutical company focused on developing, acquiring and commercializing products that treat dermatologic conditions and diseases, and improve the appearance of skin. Through the Company's own sales force, it markets

Axol Bioscience

We specialize in human cell culture. Whether you need iPSC-derived cells, disease models, human primary cells or culture media, were here for you.

Ansa Biotechnologies

Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods.

QurAlis

QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. We are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus our programs on tackling specific disease-causing mechanisms.